01187-A: The Role of mTOR in Canine Lymphoma
Grant Status: Closed
Project SummaryLymphoma is the most common malignant tumor in the dog. It is a highly aggressive cancer and while most dogs achieve remission with chemotherapy treatment the lymphoma usually returns within a year and eventually leads to their death. The AKT/mTOR pathway is turned on in many forms of human cancer, including lymphosarcoma and other hematologic malignancies. In this study we have identified that the AKT/mTOR pathway is present and active in four canine lymphoma cell lines. Further we have found that we can slow cellular proliferation by treating the cells with rapamycin, which inhibits this pathway. We have also collected lymph node aspirates from dogs with lymphoma and also found that this pathway is active in dogs with lymphoma. While this work is ongoing, it supports that use of mTOR inhibitors in the reatment of lymphoma.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.